<DOC>
	<DOC>NCT02941549</DOC>
	<brief_summary>The purpose of this randomised, double-blind, placebo-controlled, parallel group study is to assess the safety and efficacy of orally administered DS102 capsules versus placebo in the treatment of adult patients with Non Alcoholic Fatty Liver Disease (NAFLD)</brief_summary>
	<brief_title>Safety And Efficacy Study Of Orally Administered DS102 In Patients With NAFLD</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Patients diagnosed with NAFLD by the presence of hepatic steatosis on imaging or histology in the absence of any secondary causes Patients with an ALT ≥ 1.5 ULN and &lt; 5 ULN on two occasions 7 or more days apart during screening Patients with a body mass index (BMI) between 25.0 and 40.0 kg/m² inclusive. Patients with a history of controlled obesity or controlled diabetes are allowed on the study Patients aged between 18 and 75 years inclusive Patients with an unstable metabolic condition such as weight change &gt; 5% in the 3 months prior to inclusion Patients with medical/surgical history of gastric bypass surgery, orthotopic liver transplant (OLT) or listed for OLT Patients with uncontrolled diabetes mellitus type 2, i.e. HbA1c ≥ 9% (75 mmol/mol) at the time of screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>